Document is current
Any future updates will be listed below
-
Authors
Sekar, Aswin
Griffin, Rosalie
Parikh, Sameer A. https://orcid.org/0000-0002-3221-7314
Genovese, Giulio
Robinson, Dennis P.
Norman, Aaron D.
Olson, Janet E. https://orcid.org/0000-0003-4944-7789
Rabe, Kari G. https://orcid.org/0000-0002-7313-1875
Hoel, Mingma S.
Boddicker, Nicholas J.
Hampel, Paul J. https://orcid.org/0000-0003-1292-3024
Kay, Neil E. https://orcid.org/0000-0002-5951-5055
Cerhan, James R. https://orcid.org/0000-0002-7482-178X
Braggio, Esteban https://orcid.org/0000-0003-3860-4830
Hanson, Curtis A.
Vachon, Celine M. https://orcid.org/0000-0002-1962-9322
Shanafelt, Tait D.
Ebert, Benjamin L. https://orcid.org/0000-0003-0197-5451
Slager, Susan L. https://orcid.org/0000-0002-5173-4712
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R21CA282702, R01CA258465, R21CA282702, R21CA282702, K00CA234943, R01CA258465, R01CA235026)
- License Information
-
More Information
Article History
Received: 4 July 2024
Revised: 14 October 2024
Accepted: 16 October 2024
First Online: 6 November 2024
Competing interests
: AS stock in Vertex Pharmaceuticals and consulting for Alight. SAP Research funding has been provided to the institution from Janssen, AstraZeneca, Merck, and Genentech for clinical studies in which Sameer A. Parikh is a principal investigator. Honoraria has been provided to the institution from Pharmacyclics, Merck, AstraZeneca, Janssen, Genentech, Amgen, MingSight Pharmaceuticals, TG Therapeutics, Eli Lilly, Novalgen Limited, Kite Pharma, and AbbVie for Sameer A. Parikh’s participation in consulting activities/advisory board meetings. PJH: None. NEK: Advisory Board for AbbVie, AstraZeneca, Beigene, Behring, Boehringer Ingelheim Pharmaceuticals, Inc., Dava Oncology, Janssen, Juno Therapeutics, Pharmacyclics. DSMC (Data Safety Monitoring Committee) for Agios Pharm, AstraZeneca, BMS –Celgene, Dren Bio Janssen. Research funding from: AbbVie, Acerta Pharma, Bristol Meyer Squib, Celgene, Genentech, Pharmacyclics, Sunesis, Vincerx. BLE: research funding from Celgene, Deerfield, Novartis, and Calico and consulting fees from Abbvie and GRAIL. He is a member of the scientific advisory board and shareholder for Neomorph Inc., TenSixteen Bio, Skyhawk Therapeutics, and Exo Therapeutics.
: All methods were performed in accordance with the relevant guidelines and regulations. All participants provided written informed consent and were from either the Mayo Clinic MBL Biobank or the Mayo Clinic CLL Database (IRB 07-005788). Data for participants from the Mass General Brigham Biobank were accessed under an approved secondary use authorization protocol (2021P000384).
